Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis.
Immunic, Inc. is headquartered in New York. Its subsidiary, Immunic AG, is based in Planegg-Martinsried, Germany, where the company’s research and development activities are conducted. Additional subsidiaries are located in Halle (Saale), Germany, and Melbourne, Australia.
The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic’s lead development program, IMU-838, is in phase 2 clinical development for relapsing-remitting multiple sclerosis and ulcerative colitis, with an additional phase 2 trial planned in Crohn’s disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic.
Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips
Read More
Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity
Read More
Immunic, Inc. to Participate in Industry and Investor Conferences in November
Read More